"Breakthrough Alzheimer's Drug Shows Promise Despite Side Effects"
TL;DR Summary
Eli Lilly's stock is surging as its Alzheimer's treatment, donanemab, shows promising results in slowing cognitive decline, making it a strong competitor to Biogen's drug. The company is also bolstering its weight-loss drug portfolio with the acquisition of Versanis Bio. Analysts project strong earnings growth for Eli Lilly, with expectations of blockbuster sales for Mounjaro and donanemab in the coming years.
- Eli Lilly Stock, IBD Stock Of The Day, Breaks Out With Tentpoles In Two Key Markets Investor's Business Daily
- US drugmaker: Alzheimer's development can be slowed down | DW News DW News
- Drug donanemab seen as turning point in dementia fight BBC
- Growing hope over a new Alzheimer's drug, but there are side effects CBC News: The National
- Pharmalittle: Data confirm benefits and risks of Lilly Alzheimer's drug; Medicare aims to pay hospitals to stockpile essential drugs STAT
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
4 min
vs 4 min read
Condensed
92%
801 → 61 words
Want the full story? Read the original article
Read on Investor's Business Daily